A Detailed Analysis of the Hypercalcemia Treatment Market Based on the Rising Hyperparathyroidism Incidences, Advancements in Therapeutic Interventions, and Regulation of Drugs for Hypercalcemia Treatment
Industry: Healthcare
Published Date: February-2024
Format: PPT*, PDF, EXCEL
Delivery Timelines: Contact Sales
Number of Pages: 223
Report ID: PMRREP34006
1. Executive Summary
1.1. Global Hypercalcemia Treatment Market Snapshot, 2023 and 2030
1.2. Market Opportunity Assessment, 2023 - 2030, US$ Mn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations
2. Market Overview
2.1. Market Scope and Definition
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Opportunity
2.2.4. Challenges
2.2.5. Key Trends
2.3. Product Lifecycle Analysis
2.4. Hypercalcemia Treatment Market: Value Chain
2.4.1. List of Raw Material Supplier
2.4.2. List of Manufacturers
2.4.3. List of Distributors
2.4.4. List of Applications
2.4.5. Profitability Analysis
2.5. Porter Five Force’s Analysis
2.6. Geopolitical Tensions: Market Impact
2.7. Macro-Economic Factors
2.7.1. Global Sectorial Outlook
2.7.2. Global GDP Growth Outlook
2.7.3. Global Parent Market Overview
2.8. Forecast Factors - Relevance and Impact
2.9. Regulatory and Product Landscape
3. Global Hypercalcemia Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
3.1. Key Highlights
3.1.1. Market Volume (Units) Projections
3.1.2. Market Size and Y-o-Y Growth
3.1.3. Absolute $ Opportunity
3.2. Market Size (US$ Mn) Analysis and Forecast
3.2.1. Historical Market Size Analysis, 2013-2016
3.2.2. Current Market Size Forecast, 2018-2026
3.3. Global Hypercalcemia Treatment Market Outlook: Product
3.3.1. Introduction / Key Findings
3.3.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Product, 2018 - 2022
3.3.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Product, 2023 - 2030
3.3.3.1. Bisphosphonates
3.3.3.1.1. Clodronate
3.3.3.1.2. Ibandronate
3.3.3.1.3. Pamidronate
3.3.3.1.4. Zoledronic Acid
3.3.3.2. Calcitonin
3.3.3.3. Glucocorticoids
3.3.3.4. Denosumab
3.3.3.5. Calcimimetics
3.4. Market Attractiveness Analysis: Product
3.5. Global Hypercalcemia Treatment Market Outlook: Distribution Channel
3.5.1. Introduction / Key Findings
3.5.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Distribution Channel, 2018 - 2022
3.5.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
3.5.3.1. Hospitals
3.5.3.2. Clinics
3.5.3.3. Independent Pharmacy & Drug Stores
3.6. Market Attractiveness Analysis: Distribution Channel
4. Global Hypercalcemia Treatment Market Outlook: Region
4.1. Key Highlights
4.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Region, 2018 - 2022
4.3. Current Market Size (US$ Mn) and Volume (Units) Forecast By Region, 2023 - 2030
4.3.1. North America
4.3.2. Europe
4.3.3. East Asia
4.3.4. South Asia and Oceania
4.3.5. Latin America
4.3.6. Middle East & Africa (MEA)
4.4. Market Attractiveness Analysis: Region
5. North America Hypercalcemia Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
5.1. Key Highlights
5.2. Pricing Analysis
5.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
5.3.1. By Country
5.3.2. By Product
5.3.3. By Distribution Channel
5.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
5.4.1. U.S.
5.4.2. Canada
5.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Product, 2023 - 2030
5.5.1. Bisphosphonates
5.5.1.1. Clodronate
5.5.1.2. Ibandronate
5.5.1.3. Pamidronate
5.5.1.4. Zoledronic Acid
5.5.2. Calcitonin
5.5.3. Glucocorticoids
5.5.4. Denosumab
5.5.5. Calcimimetics
5.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
5.6.1. Hospitals
5.6.2. Clinics
5.6.3. Independent Pharmacy & Drug Stores
5.7. Market Attractiveness Analysis
6. Europe Hypercalcemia Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
6.1. Key Highlights
6.2. Pricing Analysis
6.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
6.3.1. By Country
6.3.2. By Product
6.3.3. By Distribution Channel
6.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
6.4.1. Germany
6.4.2. France
6.4.3. U.K.
6.4.4. Italy
6.4.5. Spain
6.4.6. Russia
6.4.7. Türkiye
6.4.8. Rest of Europe
6.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Product, 2023 - 2030
6.5.1. Bisphosphonates
6.5.1.1. Clodronate
6.5.1.2. Ibandronate
6.5.1.3. Pamidronate
6.5.1.4. Zoledronic Acid
6.5.2. Calcitonin
6.5.3. Glucocorticoids
6.5.4. Denosumab
6.5.5. Calcimimetics
6.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
6.6.1. Hospitals
6.6.2. Clinics
6.6.3. Independent Pharmacy & Drug Stores
6.7. Market Attractiveness Analysis
7. East Asia Hypercalcemia Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
7.1. Key Highlights
7.2. Pricing Analysis
7.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
7.3.1. By Country
7.3.2. By Product
7.3.3. By Distribution Channel
7.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
7.4.1. China
7.4.2. Japan
7.4.3. South Korea
7.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Product, 2023 - 2030
7.5.1. Bisphosphonates
7.5.1.1. Clodronate
7.5.1.2. Ibandronate
7.5.1.3. Pamidronate
7.5.1.4. Zoledronic Acid
7.5.2. Calcitonin
7.5.3. Glucocorticoids
7.5.4. Denosumab
7.5.5. Calcimimetics
7.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
7.6.1. Hospitals
7.6.2. CLINICS
7.6.3. INDEPENDENT PHARMACY & DRUG STORES
7.7. Market Attractiveness Analysis
8. South Asia & Oceania Hypercalcemia Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
8.1. Key Highlights
8.2. Pricing Analysis
8.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
8.3.1. By Country
8.3.2. By Product
8.3.3. By Distribution Channel
8.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
8.4.1. India
8.4.2. Southeast Asia
8.4.3. ANZ
8.4.4. Rest of South Asia & Oceania
8.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Product, 2023 - 2030
8.5.1. Bisphosphonates
8.5.1.1. Clodronate
8.5.1.2. Ibandronate
8.5.1.3. Pamidronate
8.5.1.4. Zoledronic Acid
8.5.2. Calcitonin
8.5.3. Glucocorticoids
8.5.4. Denosumab
8.5.5. Calcimimetics
8.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
8.6.1. Hospitals
8.6.2. CLINICS
8.6.3. INDEPENDENT PHARMACY & DRUG STORES
8.7. Market Attractiveness Analysis
9. Latin America Hypercalcemia Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
9.1. Key Highlights
9.2. Pricing Analysis
9.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
9.3.1. By Country
9.3.2. By Product
9.3.3. By Distribution Channel
9.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Product, 2023 - 2030
9.5.1. Bisphosphonates
9.5.1.1. Clodronate
9.5.1.2. Ibandronate
9.5.1.3. Pamidronate
9.5.1.4. Zoledronic Acid
9.5.2. Calcitonin
9.5.3. Glucocorticoids
9.5.4. Denosumab
9.5.5. Calcimimetics
9.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
9.6.1. Hospitals
9.6.2. CLINICS
9.6.3. INDEPENDENT PHARMACY & DRUG STORES
9.7. Market Attractiveness Analysis
10. Middle East & Africa Hypercalcemia Treatment Market Outlook: Historical (2018 - 2022) and Forecast (2023 - 2030)
10.1. Key Highlights
10.2. Pricing Analysis
10.3. Historical Market Size (US$ Mn) and Volume (Units) Analysis By Market, 2018 - 2022
10.3.1. By Country
10.3.2. By Product
10.3.3. By Distribution Channel
10.4. Current Market Size (US$ Mn) and Volume (Units) Forecast By Country, 2023 - 2030
10.4.1. GCC
10.4.2. Egypt
10.4.3. South Africa
10.4.4. Northern Africa
10.4.5. Rest of Middle East & Africa
10.5. Current Market Size (US$ Mn) and Volume (Units) Forecast By Product, 2023 - 2030
10.5.1. Bisphosphonates
10.5.1.1. Clodronate
10.5.1.2. Ibandronate
10.5.1.3. Pamidronate
10.5.1.4. Zoledronic Acid
10.5.2. Calcitonin
10.5.3. Glucocorticoids
10.5.4. Denosumab
10.5.5. Calcimimetics
10.6. Current Market Size (US$ Mn) and Volume (Units) Forecast By Distribution Channel, 2023 - 2030
10.6.1. Hospitals
10.6.2. CLINICS
10.6.3. INDEPENDENT PHARMACY & DRUG STORES
10.7. Market Attractiveness Analysis
11. Competition Landscape
11.1. Market Share Analysis, 2022
11.2. Market Structure
11.2.1. Competition Intensity Mapping By Market
11.2.2. Competition Dashboard
11.2.3. Apparent Product Capacity
11.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
11.3.1. Amgen Inc.
11.3.1.1. Overview
11.3.1.2. Segments and Product
11.3.1.3. Key Financials
11.3.1.4. Market Developments
11.3.1.5. Market Strategy
11.3.2. Pfizer Inc.
11.3.2.1. Overview
11.3.2.2. Segments and Product
11.3.2.3. Key Financials
11.3.2.4. Market Developments
11.3.2.5. Market Strategy
11.3.3. Mylan N. V.
11.3.3.1. Overview
11.3.3.2. Segments and Product
11.3.3.3. Key Financials
11.3.3.4. Market Developments
11.3.3.5. Market Strategy
11.3.4. Sunovion
11.3.4.1. Overview
11.3.4.2. Segments and Product
11.3.4.3. Key Financials
11.3.4.4. Market Developments
11.3.4.5. Market Strategy
11.3.5. Procter And Gamble
11.3.5.1. Overview
11.3.5.2. Segments and Product
11.3.5.3. Key Financials
11.3.5.4. Market Developments
11.3.5.5. Market Strategy
11.3.6. Apotex Corporation
11.3.6.1. Overview
11.3.6.2. Segments and Product
11.3.6.3. Key Financials
11.3.6.4. Market Developments
11.3.6.5. Market Strategy
11.3.7. Genentech, Inc.
11.3.7.1. Overview
11.3.7.2. Segments and Product
11.3.7.3. Key Financials
11.3.7.4. Market Developments
11.3.7.5. Market Strategy
11.3.8. Novartis AG
11.3.8.1. Overview
11.3.8.2. Segments and Product
11.3.8.3. Key Financials
11.3.8.4. Market Developments
11.3.8.5. Market Strategy
11.3.9. Bayer AG
11.3.9.1. Overview
11.3.9.2. Segments and Product
11.3.9.3. Key Financials
11.3.9.4. Market Developments
11.3.9.5. Market Strategy
11.3.10. Hoffmann La Roche
11.3.10.1. Overview
11.3.10.2. Segments and Product
11.3.10.3. Key Financials
11.3.10.4. Market Developments
11.3.10.5. Market Strategy
11.3.11. Atnahs Pharma
11.3.11.1. Overview
11.3.11.2. Segments and Product
11.3.11.3. Key Financials
11.3.11.4. Market Developments
11.3.11.5. Market Strategy
11.3.12. Cipla Inc.
11.3.12.1. Overview
11.3.12.2. Segments and Product
11.3.12.3. Key Financials
11.3.12.4. Market Developments
11.3.12.5. Market Strategy
11.3.13. Sun Pharmaceuticals Industries Ltd
11.3.13.1. Overview
11.3.13.2. Segments and Product
11.3.13.3. Key Financials
11.3.13.4. Market Developments
11.3.13.5. Market Strategy
11.3.14. Dr. Reddy’s Laboratories
11.3.14.1. Overview
11.3.14.2. Segments and Product
11.3.14.3. Key Financials
11.3.14.4. Market Developments
11.3.14.5. Market Strategy
11.3.15. Aurobindo Pharma Limited
11.3.15.1. Overview
11.3.15.2. Segments and Product
11.3.15.3. Key Financials
11.3.15.4. Market Developments
11.3.15.5. Market Strategy
12. Appendix
12.1. Research Methodology
12.2. Research Assumptions
12.3. Acronyms and Abbreviations
Report Sample is Available
In-depth report coverage is now just a few seconds away
Get FREE Report Sample
Make This Report Your Own
Take Advantage of Intelligence Tailored to your Business Objective
Get a Customized Version
